L. K. Pearson

发表

Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability.

L. Wienkers, J. Fleishaker, G. Peters, 1996, The Journal of pharmacology and experimental therapeutics.

Hormonal Effects on Tirilazad Clearance in Women: Assessment of the Role of CYP3A

L. Wienkers, P. Pearson, J. Fleishaker, 1999, Journal of clinical pharmacology.

and pharmacokinetic effects of m r subtype selective agonist, compared to lorazepam and placebo in healthy volunteers

J. Gerven, M. Pieters, A. Cohen, 2014 .

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.

C. V. Pesheck, L L Miller, R. S. Lord, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Evaluation of the Potential Pharmacokinetic/Pharmacodynamic Interaction between Fluoxetine and Reboxetine in Healthy Volunteers

J. Fleishaker, M. Mucci, L. K. Pearson, 1999 .

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

J. Gerven, A. Cohen, M. Murphy, 2007 .

Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction.

J. Fleishaker, G. Peters, L. K. Pearson, 1995, Journal of pharmaceutical sciences.

Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis

J. Fleishaker, G. Peters, L. K. Pearson, 1996, European Journal of Clinical Pharmacology.

Gender does not affect the degree of induction of tirilazad clearance by phenobarbital

J. Fleishaker, G. Peters, L. K. Pearson, 1996, European Journal of Clinical Pharmacology.

Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.

L. Wienkers, J. Fleishaker, G. Peters, 1998, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F.

B. Gomez-Mancilla, J. Fleishaker, S. Freestone, 1999, International journal of clinical pharmacology and therapeutics.

Induction of tirilazad clearance by phenytoin

G. Peters, L. K. Pearson, J. C. Fleishaker, 1998, Biopharmaceutics & drug disposition.

Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.

L. Wienkers, L. K. Pearson, J. C. Fleishaker, 1998, The Journal of pharmacology and experimental therapeutics.